Antibody-drug conjugate · Cytotoxic, directed at receptor tyrosine kinase-like orphan receptor 1 (ROR1) · developed by Immunome
IM-1021 is an antibody-drug conjugate in which an IgG1 monoclonal antibody binds ROR1 on tumor cells and delivers the topoisomerase I inhibitor HC74 via a cleavable linker. After internalization, released HC74 inhibits DNA replication, causing cell cycle arrest and apoptosis, and it can also act on neighboring tumor cells. It is being studied in solid and hematologic malignancies.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06823167 | Phase 1 | Solid Malignancies | Recruiting | IMNM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Hematologic MalignanciesSolid Malignancies
Updated Oct 18, 2026. Something wrong or missing? Report it on the IMNM page.
See IMNM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IMNM catalysts and pipeline →